Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis

Đurić-Filipović, Ivana; Caminati, Marco; Kostić, Gordana; Filipović, Đorđe; Živković, Zorica

doi:10.1007/s12519-016-0022-1

Cited by 16 publications

(17 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent review summarized over 80 randomized double-blind placebo-controlled trials, and several reviews of both adult and children populations and concluded that, in most studies, the overall occurrence of systemic side effects is similar between placebo and active groups (7). To date, only few cases of anaphylaxis have been reported with SLIT (38), and some of these are probably due to overdose (72). …”

Section: Safetymentioning

confidence: 99%

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children

Tsabouri

Mavroudi

Feketea³

et al. 2017

Front. Pediatr.

View full text Add to dashboard Cite

This review presents up-to-date understanding of immunotherapy in the treatment of children with allergic asthma. The principal types of allergen immunotherapy (AIT) are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both of them are indicated for patients with allergic rhinitis and/or asthma, who have evidence of clinically relevant allergen-specific IgE, and significant symptoms despite reasonable avoidance measures and/or maximal medical therapy. Studies have shown a significant decrease in asthma symptom scores and in the use of rescue medication, and a preventive effect on asthma onset. Although the safety profile of SLIT appears to be better than SCIT, the results of some studies and meta-analyses suggest that the efficacy of SCIT is better and that SCIT has an earlier onset than SLIT in children with allergic asthma. Severe, not controlled asthma, and medical error were the most frequent causes of SCIT-induced adverse events.

show abstract

Section: Safetymentioning

confidence: 99%

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children

Tsabouri

Mavroudi

Feketea³

et al. 2017

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…High level of anxiety as well as higher incidence of depression and other physiological disorders can be seen in children and adolescents with asthma, allergic rhinitis and atopic dermatitis. A certain number of studies confirmed the impact of SLIT on all previous mentioned aspects of quality of life [76,77].…”

Section: Clinical Efficacy Of Slit Still Matter Of a Debatementioning

confidence: 74%

Current Issues on Immunotherapy in Children

Djuric-Filipovic¹,

Živanović²,

Kostić³

et al. 2017

Allergen

Self Cite

View full text Add to dashboard Cite

Therapy of allergic diseases in children implicates avoidance of allergens, standard pharmacotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic diseases with the ability to change the natural course of the disease, thus stopping its further progression as well as the development of new allergic diseases and new sensibilizations. The objective of this chapter is to give insight into the latest data on immunotherapy in treating children with allergic diseases. Methods: The study involved a search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous studies have shown that the sublingual application of allergen-specific immunotherapy is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated allergic diseases of the respiratory tract in children, but there are still some questions to be solved concerning the usage of SLIT in children younger than 5 years old, SLIT for polysensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order to improve the clinical efficacy of SLIT, we are looking for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.

show abstract

“…They are easily contained by transitorily diminishing the dose or antihistamine premedication for several weeks. Systemic reactions and asthma exacerbations are not common [ 79 ], while anaphylaxis has been reported anecdotally [ 85 , 86 ], and no fatality has been registered. A very low percentage of patients discontinues SLIT because of side effects [ 20 , 39 , 85 ].…”

Section: Safetymentioning

confidence: 99%

Use of Sublingual Immunotherapy for Aeroallergens in Children with Asthma

Caffarelli

Mastrorilli

Procaccianti

et al. 2020

JCM

View full text Add to dashboard Cite

Asthma is a heterogeneous disease that in children is often allergen-driven with a type 2 inflammation. Sublingual immunotherapy represents an important progress in the use of personalized medicine in children with allergic asthma. It is a viable option for house dust mite-driven asthma and in subjects with the asthma associated with allergic rhinitis. The use and indications for isolated asthma caused by other allergens are still controversial owing to heterogeneity of commercially available products and methodological limitations of studies in children. Nevertheless, most studies and meta-analyses found the efficacy of sublingual immunotherapy. Sublingual immunotherapy is safe but cannot be recommended in children with uncontrolled asthma.

show abstract

Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis

Abstract: At least 3 years of treatment and stable asthma before the immunotherapy are positive predictors of good clinical efficacy and tolerability of SLIT. SLIT reduces the symptoms of allergic diseases and the use of medicaments, and improves the quality of life of children with the diseases.

Cited by 16 publications

References 76 publications

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children

Current Issues on Immunotherapy in Children

Use of Sublingual Immunotherapy for Aeroallergens in Children with Asthma

Contact Info

Product

Resources

About